Diabetic kidney disease: Act now or pay later

Medical Journal of Australia

Volumn 192, Issue 5, 2010, Pages 272-274

  Atkins, Robert C ^a   Zimmet, Paul Z ^b  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; LIPID; ANGIOTENSIN RECEPTOR;

ALBUMINURIA; AUSTRALIA; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MONITORING; DEVELOPING COUNTRY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETOGENESIS; DISEASE COURSE; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GOVERNMENT; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH EDUCATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY INJURY; LAW; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PUBLIC HEALTH PROBLEM; RENAL REPLACEMENT THERAPY; REVIEW; SCREENING; SIGNAL TRANSDUCTION; UNITED NATIONS; ARTICLE; DRUG ANTAGONISM; HEALTH; LIFESTYLE; PATHOPHYSIOLOGY;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HUMANS; LIFE STYLE; RECEPTORS, ANGIOTENSIN; WORLD HEALTH;

EID: 77950601043     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03506.x     Document Type: Review

References (30)

1. International Diabetes Federation and International Society of Nephrology. Diabetes and kidney disease: time to act. Brussels: IDF and ISN, 2003.
2. Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787. (Pubitemid 34000780)
3. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431.
4. Yoon K, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 1681-1688. (Pubitemid 46048556)
5. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. Diabetes atlas, 3rd ed. Brussels: International Diabetes Federation, 2006: 15-109.
6. Reutens AT, Prentice L, Atkins R. The epidemiology of diabetic kidney disease. In: Ekoé J, Rewers M, Williams R, Zimmet P, editors. The epidemiology of diabetes mellitus. 2nd ed. Chichester: John Wiley and Sons, 2008: 499-518.
7. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. International comparisons. In: 2007 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: NIH and NIDDKD, 2007: 239-254.
8. McDonald S, Excell L, Livingston B, editors. Appendix II. In: ANZDATA Registry Report 2008. Adelaide: Australia and New Zealand Dialysis and Transplant Registry, 2008: 1-97.
9. Yamagata K, Iseki K, Nitta K, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 2008; 12: 1-8.
10. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long term implications. J Am Soc Nephrol 2002; 13 Suppl 1: S37-S40.
11. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
12. Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-1839. (Pubitemid 44324140)
13. Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69: 2057-2063. (Pubitemid 43924271)
14. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-1821.
15. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829-834.
16. White SL, Polkinghorne KR, Cass A, et al. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust 2008; 188: 204-208.
17. Whaley-Connell A, Sowers JR, McCullough PA, et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009; 53 (4 Suppl 4): 11S-21S.
18. Thomas M, Viberti G, Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point? Nat Clin Pract Nephrol 2008; 4: 2-3.
19. Holman RR, Paul SK, Bethal MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
20. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 2008; 25 Suppl 2: S25-S29.
21. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591. (Pubitemid 351214285)
22. Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840. (Pubitemid 47362321)
23. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
24. Zoungas S, de Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from the ADVANCE trial. Diabetes Care 2009; 32: 2068-2074.
25. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
26. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
27. Lewis E, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
28. Burney B, Kalaitzidis R, Bakris G. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens 2009; 18: 107-111.
29. International Society of Nephrology. Program for detection, and management of chronic kidney disease, hypertension, diabetes and cardiovascular disease in developing countries. KHDC program. 15 February 2005. http://www.nature.com/isn/education/guidelines/isn/pdf/ed-051027-2x1.pdf (accessed Jan 2010).
30. National Kidney Foundation [United States]. Kidney Early Evaluation Program. http://www.kidney.org/news/keep/index.cfm (accessed Jan 2010).